Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the ...
ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, ...
In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary ...
Expert and company perspectives on the role of amivantamab in advancing first-line treatment “Patients with recurrent or metastatic head and neck cancer continue to face a poor prognosis, highlighting ...
Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline. NANJING, China, ...
Safety and Efficacy of the Anti-EGFR/B7H3 Bispecific ADC IBI3001 in Patients with Advanced Solid Tumors: Results from a Multi ...
At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase ...
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, ...
Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± ...
Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five ...
Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated ...
Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results